Marcus Kelly Email and Phone Number
Marcus Kelly work email
- Valid
Marcus Kelly personal email
- Valid
Marcus Kelly phone numbers
I am an experienced team leader driving drug development efforts on an array of novel targeted therapeutics. I have over 15 years experience in monoclonal antibody based therapeutics including antibody-drug conjugates (ADCs) and T-cell engaging bispecifics. I have also developed Immuno-PET imaging agents and targeted radionuclide therapies.I have worked across all stages of the development process from target discovery and validation through to in vivo pharmacology and IND enabling studies.
-
Associate Director - PharmacologyEikon Therapeutics Apr 2023 - PresentHayward, Ca, Us
-
Associate Director, Oncology & Immune-OncologyRegeneron Pharmaceuticals, Inc. Jan 2020 - Apr 2023Tarrytown, New York, Us -
Senior Staff Scientist, Oncology & AngiogenesisRegeneron Pharmaceuticals, Inc. Jan 2017 - Jan 2020Tarrytown, New York, Us
-
Staff Scientist, Oncology & AngiogenesisRegeneron Pharmaceuticals, Inc. Jan 2014 - Dec 2016Tarrytown, New York, Us
-
Scientist, Oncology & AngiogenesisRegeneron Pharmaceuticals, Inc. Oct 2010 - Dec 2013Tarrytown, New York, UsI am involved in the development on novel monoclonal antibody based cancer therapeutics. Through target validation, in vitro cell biology and in vivo pharmacology I work to advance a number of drug candidates targeting an array of cancer associated antibody targets.
-
Postdoctoral Research FellowLudwig Institute For Cancer Research May 2008 - Oct 2010New York, Ny, UsMy postdoctoral research chiefly involved assessing the efficacy of arginine deprivation resulting from treatment with pegylated Arginine Deiminase (ADI-PEG20) in small cell lung cancer. The results assessing ADI-PEG20 in SCLC for the first time were published in the British Journal of Cancer, and a Phase II clinical trial assessing ADI-PEG20 in SCLC has been initiated (NCT01266018). -
Visiting ScientistLudwig Institute For Cancer Research Jul 2007 - May 2008New York, Ny, UsUndertook a study of the effects of anti-EGFR monoclonal antibodies 528 and 806 on the oligomerization state of the receptor using advanced microscopy techniques.
-
Phd StudentLudwig Institute For Cancer Research 2003 - 2007New York, Ny, UsMy graduate PhD project focused on the preclinical development of the anti-Lewis Y monoclonal antibody hu3S193. I assessed the use of the antibody using alpha and beta emitting radionuclides in the radioimmunotherapy of various tumor xenograft models both as single agent and combined with taxane chemotherapies.
Marcus Kelly Skills
Marcus Kelly Education Details
-
University Of MelbourneAntibody Pharmacology -
University Of MelbournePharmacology And Pathology
Frequently Asked Questions about Marcus Kelly
What company does Marcus Kelly work for?
Marcus Kelly works for Eikon Therapeutics
What is Marcus Kelly's role at the current company?
Marcus Kelly's current role is Associate Director - Pharmacology at Eikon Therapeutics.
What is Marcus Kelly's email address?
Marcus Kelly's email address is ma****@****ron.com
What is Marcus Kelly's direct phone number?
Marcus Kelly's direct phone number is +191484*****
What schools did Marcus Kelly attend?
Marcus Kelly attended University Of Melbourne, University Of Melbourne.
What skills is Marcus Kelly known for?
Marcus Kelly has skills like Cell, Cell Culture, Cell Biology, In Vitro, Antibodies, Cancer, In Vivo, Drug Discovery, Monoclonal Antibodies, Clinical Trials, Validation, Microscopy.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial